Thyroid Eye Disease Market Size is valued at USD 2.26 billion in 2024 and is predicted to reach USD 4.02 billion by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034.
Thyroid Eye Disease is an autoimmune condition that causes eye swelling, bulging, and pain, often linked to Graves' disease. Treatments include Tepezza, corticosteroids, and surgery to reduce symptoms like eye bulging and vision problems.
Improved healthcare settings, improvements in autoimmune disease treatment, and positive patient compliance percentage are factors expected to drive the growth of the global Thyroid Eye Disease market. Increasing research & development activities and rising investment are some of the other factors expected to augment the target market growth. The increasing adoption of artificial tears and lubricating eye drops to alleviate dryness and give temporary relief from discomfort globally is expected to boost the market expansion in the coming years.
However, the high cost of Thyroid Eye Disease and lack of a clear thyroid eye treatment, coupled with the COVID-19 outbreak, are factors that may limit growth of the target market during the forecast period. Furthermore, increasing R&D activities, government actions to use sustainable components for production, investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Thyroid Eye Disease market over the forecast period.
The Thyroid Eye Disease market is segmented on the basis of marketed treatment and pipeline treatment. Based on the marketed treatment, the market is segmented as tepezza (Teprotumumab). By pipeline treatment, the market is segmented into VRDN 001, VB 421, batoclimab, and linsitinib.
The TEPEZZA (Teprotumumab) category is expected to hold a major share of the global Thyroid Eye Disease market in 2023. This is attributed to help in reducing eye bulges and double vision. Additionally, it also decreases the signs and symptoms of thyroid eye disease, including eye pain, edema, and eye disease.
The VRDN-001 segment is projected to grow at a rapid rate in the global Thyroid Eye Disease market owing to growing use in treating several fatal diseases. The VRDN-001 is an intravenous monoclonal antibody that goals the anti-insulin-like growth factor-1 receptor. The major benefit of using VRDN-001 in treating these diseases is that they are taken from a biological source.
The North America Thyroid Eye Disease market is expected to report the most increased market share in terms of revenue. This can be attributed to the strong focus on the treatment of thyroid eye disease in the region. In addition, the growing prevalence of several thyroid diseases and advancement in treatment options for Thyroid Eye Disease is also expected to increase the growth of the target market. Growing healthcare setups and rising research and development activities in the region are factors increasing the growth of the target market in the region. In addition, the region Asia Pacific is projected to grow rapidly in the global Thyroid Eye Disease market due to growing concerns about thyroid eye disease, increasing healthcare expenditure, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 2.26 Bn |
|
Revenue Forecast In 2034 |
USD 4.02 Bn |
|
Growth Rate CAGR |
CAGR of 6.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Marketed Products, Pipeline treatment |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Thyroid Eye Disease Market Snapshot
Chapter 4. Global Thyroid Eye Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2021-2034
4.8. Global Thyroid Eye Disease Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Thyroid Eye Disease Industry Trends
Chapter 5. Thyroid Eye Disease Market Segmentation 1: By Marketed Products, Estimates & Trend Analysis
5.1. Market Share By Marketed Products, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Marketed Products:
5.2.1. TEPEZZA (Teprotumumab)
Chapter 6. Thyroid Eye Disease Market Segmentation 2: By Pipeline Drugs, Estimates & Trend Analysis
6.1. Market Share by Pipeline Drugs, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Pipeline Drugss:
6.2.1. VRDN-001
6.2.2. VB421
6.2.3. Batoclimab
6.2.4. Linsitinib
Chapter 7. Thyroid Eye Disease Market Segmentation 5: Regional Estimates & Trend Analysis
7.1. Global Thyroid Eye Disease Market, Regional Snapshot 2024 & 2034
7.2. North America
7.2.1. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.2.3. North America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.3. Europe
7.3.1. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.3.3. Europe Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.4.3. Asia Pacific Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.5. Latin America
7.5.1. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.5.3. Latin America Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
7.6. Middle East & Africa
7.6.1. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts By Marketed Products, 2021-2034
7.6.3. Middle East & Africa Thyroid Eye Disease Market Revenue (US$ Million) Estimates and Forecasts by Pipeline Drugs, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Horizon Therapeutics
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Offerings
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Viridian Therapeutics
8.2.3. Pierre Fabre/ACELYRIN
8.2.4. HanAll Biopharma/Harbour BioMed/Immunovant
8.2.5. Sling Therapeutics
8.2.6. Other Prominent Players
Thyroid Eye Disease Market By Marketed Products-
Thyroid Eye Disease Market By Pipeline Treatment-
Thyroid Eye Disease Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
